Trial Profile

A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalzanemdor (Primary)
Indications Cognition disorders; Huntington's disease
Focus Therapeutic Use
Acronyms DIMENSION
Sponsors Sage Therapeutics

Most Recent Events

20 Nov 2024 According to Sage Therapeutics media release, based on results, the Company does not plan further development of dalzanemdor.
20 Nov 2024 Primary endpoint has not been met. (Symbol Digit Modalities Test (SDMT)), according to Sage Therapeutics media release.
20 Nov 2024 Results presented in the Sage Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com